<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01580202</url>
  </required_header>
  <id_info>
    <org_study_id>AI463-246</org_study_id>
    <nct_id>NCT01580202</nct_id>
  </id_info>
  <brief_title>Comparison of Prophylactic Antiviral Efficacy in Patients Undergoing Chemotherapy: Entecavir Versus Lamivudine</brief_title>
  <official_title>A Randomized, Open Labeled, Multicenter Study Comparing Entecavir Versus Lamivudine as Antiviral Prophylaxis for Patients With Hepatitis B Infection Undergoing Cytotoxic Chemotherapy for Malignant Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with chronic hepatitis B who are undergoing anticancer chemotherapy are at risk of&#xD;
      HBV reactivation and hepatitis flare. Lamivudine (LAM) prophylaxis has been recommended in&#xD;
      such circumstance according to the practice guidelines despite of limited evidence. However,&#xD;
      failure of LAM prophylaxis including virologic breakthrough and withdrawal hepatitis occurs&#xD;
      occasionally, which may lead to liver-related morbidity and mortality as well as premature&#xD;
      interruption or a delay of chemotherapy. Given relatively frequent drug resistance of LAM,&#xD;
      studies on the proper prophylactic antiviral regimen is warranted. The present multicenter,&#xD;
      prospective, randomized study aims to compare the effect of entecavir (ETV) versus LAM for&#xD;
      the prevention of HBV reactivation in HBsAg-positive patients with hematologic and oncologic&#xD;
      malignancy undergoing cytotoxic chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic hepatitis B virus (HBV) carriers who are undergoing anticancer chemotherapy are at&#xD;
      risk of HBV reactivation and hepatitis flare, and lamivudine (LAM) prophylaxis is recommended&#xD;
      according to the practice guidelines despite of limited evidence. However, failure of LAM&#xD;
      prophylaxis defined as virologic breakthrough during LAM therapy and withdrawal hepatitis&#xD;
      after discontinuation of LAM therapy occurs occasionally, which may lead to liver-related&#xD;
      morbidity and mortality as well as premature interruption or a delay of chemotherapy.&#xD;
      Considering that LAM therapy showed relatively higher rates of drug resistance and of&#xD;
      withdrawal hepatitis, studies on the better choice of prophylactic antiviral regimen is&#xD;
      warranted.&#xD;
&#xD;
      The purpose of our study is to conduct a multicenter, prospective, randomized study comparing&#xD;
      the effect of entecavir (ETV) versus LAM for the prevention of HBV reactivation in&#xD;
      HBsAg-positive patients with hematologic and oncologic malignancy undergoing cytotoxic&#xD;
      chemotherapy.&#xD;
&#xD;
      A total one hundred eighty HBV carriers with malignancy undergoing chemotherapy will be&#xD;
      randomly assigned to each prophylactic therapy arm of ETV and LAM group. The primary endpoint&#xD;
      of the study is the HBV reactivation rate during antiviral therapy and 6 months after&#xD;
      discontinuation of prophylactic antiviral therapy.&#xD;
&#xD;
      If the prophylactic efficacy of ETV is superior to that of LAM, ETV will be the preferred&#xD;
      prophylactic therapy for HBsAg-positive cancer patients undergoing chemotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The cumulative probability of HBV reactivation</measure>
    <time_frame>From the time of randomization until 24week after discontinuation of antiviral prophylaxis</time_frame>
    <description>10-fold or more elevation in serum HBV DNA titers above nadir</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of HBV-related hepatitis flare</measure>
    <time_frame>From the time of randomization until 24week after discontinuation of antiviral prophylaxis</time_frame>
    <description>greater than 3-fold increase of ULN (upper limit of a normal reference value) of a serum ALT level that exceeded 100 IU/L during antiviral prophylaxis and 24 week after discontinuation of antiviral prophylaxis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative probability of emergence of genotypic resistance</measure>
    <time_frame>From the time of randomization until 24week after discontinuation of antiviral prophylaxis</time_frame>
    <description>detection of mutations that have been shown in in vitro studies to confer resistance to either ETV or LAM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hepatic decompensation and liver-related mortality</measure>
    <time_frame>From the time of randomization until 24week after discontinuation of antiviral prophylaxis</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Malignancy</condition>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Lamivudine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LAM (100 mg/day) will be started within 1 week prior to initiation of the 1st cycle of chemotherapy, and continued until 24 weeks after completion of the last chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Entecavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ETV (0.5 mg/day) will be started within 1 week prior to initiation of the 1st cycle of chemotherapy, and continued until 24 weeks after completion of the last chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>Entecavir 0.5mg daily per os</description>
    <arm_group_label>Entecavir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <description>lamivudine 100mg daily per os</description>
    <arm_group_label>Lamivudine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  positive for HBsAg for at least 6 months&#xD;
&#xD;
          -  inactive or active carrier of HBV with ALT level &lt;2xULN, chronic hepatitis and&#xD;
             compensated cirrhosis (Child-Pugh class A)&#xD;
&#xD;
          -  malignant tumors: non-Hodgkin's lymphoma undergoing systemic chemotherapy; solid&#xD;
             tumors undergoing chemotherapy (including adjuvant/neoadjuvant chemotherapy or&#xD;
             concurrent chemoradiation therapy)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  positive for anti-HCV or anti-HIV antibodies&#xD;
&#xD;
          -  decompensated cirrhosis or hepatocellular carcinoma&#xD;
&#xD;
          -  expected survival of less than 1 year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sook-Hyang Jeong, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Center, Korea</name>
      <address>
        <city>Goyang</city>
        <state>Gyeonggi</state>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soon Chun Hyang University Bucheon Hospital</name>
      <address>
        <city>Bucheon-si</city>
        <zip>14584</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Boramae Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>156-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>April 4, 2012</study_first_submitted>
  <study_first_submitted_qc>April 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2012</study_first_posted>
  <last_update_submitted>June 28, 2017</last_update_submitted>
  <last_update_submitted_qc>June 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Sook-Hyang Jeong</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>malignancy</keyword>
  <keyword>hepatitis B</keyword>
  <keyword>lamivudine</keyword>
  <keyword>entecavir</keyword>
  <keyword>prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

